for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Natera Inc

NTRA.OQ

Latest Trade

51.33USD

Change

-1.54(-2.91%)

Volume

201,937

Today's Range

51.02

 - 

53.01

52 Week Range

16.89

 - 

56.46

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
52.87
Open
53.00
Volume
201,937
3M AVG Volume
15.98
Today's High
53.01
Today's Low
51.02
52 Week High
56.46
52 Week Low
16.89
Shares Out (MIL)
79.72
Market Cap (MIL)
4,162.21
Forward P/E
-24.74
Dividend (Yield %)
--

Next Event

Natera Inc Annual Shareholders Meeting

Latest Developments

More

Natera Files Additional Suit Against Archerdx

Natera Reports Q2 Loss Per Share Of $0.75

Natera Files Patent Suit Against Progenity, Inc.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Natera Inc

Natera, Inc. is a diagnostics company. The Company is engaged in the discovery, development and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children; Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing, to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father(s).

Industry

Biotechnology & Drugs

Contact Info

201 Industrial Rd Ste 410

SAN CARLOS, CA

94070-2396

United States

+1.650.2499090

http://www.natera.com

Executive Leadership

Matthew Rabinowitz

Executive Chairman of the Board, Co-Founder

Steven Leonard Chapman

President, Chief Executive Officer, Director

Jonathan Sheena

Co-Founder, Chief Technology Officer, Director

Michael Burkes Brophy

Chief Financial Officer

Robert A. Schueren

Chief Operating Officer

Key Stats

1.67 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.2K

2018

0.3K

2019

0.3K

2020(E)

0.4K
EPS (USD)

2017

-2.560

2018

-2.220

2019

-1.790

2020(E)

-2.517
Price To Earnings (TTM)
--
Price To Sales (TTM)
12.63
Price To Book (MRQ)
16.06
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
47.49
LT Debt To Equity (MRQ)
28.15
Return on Investment (TTM)
-47.52
Return on Equity (TTM)
-30.75

Latest News

Latest News

BRIEF-Natera Announces First Patient Enrollments In CIRCULATE-Japan and BESPOKE CRC Trials

* NATERA - ANNOUNCES FIRST PATIENT ENROLLMENTS IN CIRCULATE-JAPAN, BESPOKE CRC TRIALS USING SIGNATERA MRD TESTING Source text for Eikon: Further company coverage:

BRIEF-Natera Files Patent Suit Against Progenity, Inc.

* NATERA INC - SUIT ALLEGES USE AND SALE OF PROGENITY'S NON-INVASIVE PRENATAL TEST INFRINGE SIX ASSERTED PATENTS

BRIEF-Natera Launches Quantification Technique To Enhance Prospera Test Precision

* NATERA LAUNCHES QUANTIFICATION TECHNIQUE TO ENHANCE PROSPERA™ TEST PRECISION; INITIATES PEDAL STUDY FOR NEW INSIGHTS Source text for Eikon: Further company coverage:

BRIEF-Natera And Illumina Settle Patent Dispute

* ILLUMINA INC - TERMS OF SETTLEMENT BENEFIT BOTH PARTIES, AND SUPPLY AGREEMENT HAS BEEN EXTENDED UNTIL 2030.

BRIEF-Natera Inc Says Prospera Receives Positive Medicare Coverage

* NATERA INC - NORIDIAN HAS ISSUED POSITIVE COVERAGE FOR PROSPERA DONOR-DERIVED CELL-FREE DNA (DD-CFDNA) TEST Source text for Eikon: Further company coverage:

BRIEF-Natera Asserts Three New Oncology Patents Against Archerdx

* NATERA INC - 3 NEW PATENTS EXPAND SCOPE OF CO'S ONGOING PATENT INFRINGEMENT LAWSUIT AGAINST ARCHERDX Source text for Eikon: Further company coverage:

BRIEF-Natera To Offer $250 Million Convertible Senior Notes Due 2027

* NATERA TO OFFER $250 MILLION CONVERTIBLE SENIOR NOTES DUE 2027

BRIEF-Natera Inc Says Withdrawing Its Financial Guidance For 2020 Fiscal Year

* NATERA ANNOUNCES PRELIMINARY FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-Natera Announces Expansion In Coverage Of Panorama Test To All Pregnant Women

* NATERA INC - EXPANSION IN COVERAGE OF ITS PANORAMA TEST TO ALL PREGNANT WOMEN, REGARDLESS OF AGE Source text for Eikon: Further company coverage:

BRIEF-Natera Provides Remote Access To Tests Without Requiring Live Office Visits

* NATERA PROVIDES REMOTE ACCESS TO TESTS WITHOUT REQUIRING LIVE OFFICE VISITS Source text for Eikon: Further company coverage:

BRIEF-Natera Terminates License, Development, Distribution Deal With Qiagen

* NATERA INC - EFFECTIVE MAR 8, CO TERMINATED LICENSE, DEVELOPMENT, DISTRIBUTION DEAL WITH QIAGEN Source : (http://bit.ly/2TYuLY8) Further company coverage:

BRIEF-Natera Posts Quarterly Loss Per Share of 46 Cents

* NATERA REPORTS FOURTH QUARTER AND YEAR 2019 FINANCIAL RESULTS

BRIEF-Natera Filed Suit Against Caredx Alleging Caredx Used "False & Misleading" Claims About Performance Capabilities Of Allosure Test

* NATERA - FILED SUIT AGAINST CAREDX ALLEGING CAREDX USED "FALSE & MISLEADING" CLAIMS ABOUT PERFORMANCE CAPABILITIES OF ALLOSURE TEST Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Elicio And Natera To Collaborate For Pancreatic Cancer Study Of Eli-002

* ELICIO THERAPEUTICS AND NATERA TO COLLABORATE IN PHASE I/II PANCREATIC CANCER STUDY OF ELI-002

BRIEF-Caredx's Patent Rights Upheld By Delaware Court

* CAREDX - COURT RECOMMENDED DENIAL OF NATERA INC.'S & EUROFINS VIRACOR INC.'S MOTIONS TO DISMISS CAREDX'S PATENT INFRINGEMENT COMPLAINTS AGAINST THEM

IN BRIEF: Judge won’t dismiss patent suit over Natera’s kidney transplant rejection test

A patent infringement lawsuit by Stanford University and licensee CareDx Inc against genetic testing company Natera Inc survived a motion to dismiss on Tuesday in U.S. District Court in Delaware.

CareDx adds false advertising claims to patent dispute with Natera

Medical diagnostics company CareDx Inc on Wednesday escalated a legal battle with rival Natera Inc over kidney transplant technology, adding false advertising claims in a new lawsuit to what began as a patent dispute.

Diagnostics firm Natera hit with patent case over kidney transplant test

Medical diagnostics company CareDx Inc on Tuesday filed a lawsuit accusing larger rival Natera Inc of using patented organ transplantation technology without authorization.

BRIEF-Natera Q1 Loss Per Share $0.61

* Q1 EARNINGS PER SHARE VIEW $-0.59 -- THOMSON REUTERS I/B/E/S

BRIEF-Natera Reports Q4 Loss Per Share $0.87

* NATERA REPORTS FOURTH QUARTER AND FISCAL YEAR 2017 FINANCIAL RESULTS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up